Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 7/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967629 | 0.87 | HTR2C (0.79) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6421112 | 0.85 | HTR6 (0.52) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL9057430 | 0.85 | KDM4E (0.79) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Hydrochloric Acid SCHEMBL30396890 | 0.85 | KDM4E (0.79) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6422813 | 0.83 | HTR6 (0.49) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6422250 | 0.82 | HTR6 (0.46) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6424059 | 0.82 | HDAC6 (0.52) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6421287 | 0.82 | HTR6 (0.46) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6423027 | 0.81 | HDAC6 (0.67) | HTR6HDAC6HDAC1 | |
| Trifluoroacetic Acid SCHEMBL6422091 | 0.81 | HDAC6 (0.48) | HTR2AHTR2CKDM4EALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| EP-2162451-A2 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | Neurogen Corporation (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009003003-A2 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002855-A1 | PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES | HRH3, HRH4, HRH1 | HTR2A 108/4885HTR2C 90/4885KDM4E 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.